HBP News and Press, Huttig Building Products Inc. From 08/04/20

Q3 F2020 financial results. The company reported the third quarter fiscal year ended April 30, 2020. Net operating loss was $2.5 million for the quarter with $1.5 million research and development expenses and $0.9 million general and administrative expenses. Helix reported ($0.02) EPS. Updating ...

The following slide deck was published by Huttig Building Products, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Gainers:  Alterity Therapeutics (NASDAQ: ATHE ) +210% . More news on: Alterity Therapeutics Limited, SilverSun Technologies, Inc., Universal Security Instruments, Inc., Stocks on the move, , Read more ...

Second Quarter 2020 Highlights (as compared to prior year quarter): Net sales decreased 12.1% to $192.0 million Gross margin of 20.2% compared to 20.3% Operating income of $2.5 million, net of $1.5 million restructuring charge.  Operating income before restructuring charg...

Cheap Stocks To Watch During The First Week Of August What’s the definition of penny stocks ? If you go by the standard Securities And Exchange Commission overview, these are simply stocks under $5. While some might immediately assume that the exchange plays a factor, for the most pa...

Gainers:  Sonnet BioTherapeutics (NASDAQ: SONN ) +97% . More news on: Sonnet BioTherapeutics Holdings, Inc., Zion Oil & Gas, Inc., Fluidigm Corporation, Stocks on the move, , Read more ...

RICHMOND HILL, Ontario, July 30, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, ...

ST. LOUIS, July 17, 2020 (GLOBE NEWSWIRE) -- Huttig Building Products (Nasdaq: HBP), one of the nation's largest wholesale distributors of millwork and specialty building products used principally in new residential construction and home improvement, plans to release its second quarter 2020...

RICHMOND HILL, Ontario, June 26, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“ Helix ” or the “ Company ”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technologica...

RICHMOND HILL, Ontario, June 22, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be pre...